Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors

  • Authors:
    • Chiara Carlomagno
    • Elide Matano
    • Roberto Bianco
    • Carolina Cimminiello
    • Antonella Prudente
    • Clorindo Pagliarulo
    • Anna Crispo
    • Lucia Cannella
    • Alfonso De Stefano
    • Francesco Paolo D'Armiento
    • Sabino De Placido
  • View Affiliations

  • Published online on: July 1, 2010     https://doi.org/10.3892/etm_00000096
  • Pages: 611-617
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the toxicity and efficacy of the FOLFOX-4 regimen as adjuvant chemotherapy in patients with gastric cancer after radical surgery. Fifty-four patients (1 stage Ib, 6 stage II, 22 stage IIIa, 14 stage IIIb and 11 stage IV) received 8-12 cycles of FOLFOX-4 (oxaliplatin 85 mg/m2, Day 1; leucovorin 100 mg/m2 i.v., Days 1 and 2; 5-fluorouracil 400 mg/m2 i.v. bolus, Days 1 and 2 and 600 mg/m2 in 22 h i.v. continuous infusion, Days 1 and 2; every 14 days). Toxicity was recorded at each cycle according to the National Cancer Institute Common Toxicity Criteria. Disease-free (DFS) and overall survival (OS) were calculated according to the Kaplan-Meier method. Thirty-eight patients (70.4%) completed the prescribed number of cycles of chemotherapy. The toxicity was mild. Grade 3-4 neutropenia occurred in 57% of patients, thrombocytopenia and anemia in 2% of cases. Peripheral neuropathy was experienced by 46% of the patients (grade 4 in 2% of cases). Five patients experienced grade 3 gastrointestinal toxicity. After a median follow-up of 33.1 months, 17 patients relapsed and 17 succumbed to the disease. The mean observed DFS and OS were 49.7 months (range 40.7-58.8) and 57.9 months (range 49.6-66.2), respectively. At univariate analysis, females and patients who had received <8 cycles of chemotherapy had a significantly worse probability of DFS and OS. The Cox model showed gender to be independent of the factors affecting DFS. Adjuvant FOLFOX-4 is feasible and well-tolerated in patients radically resected for gastric cancer. Receiving <4 months of adjuvant FOLFOX-4 could be detrimental to prognosis.
View Figures
View References

Related Articles

Journal Cover

July-August 2010
Volume 1 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, De Stefano A, D'Armiento FP, D'Armiento FP, et al: Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors . Exp Ther Med 1: 611-617, 2010
APA
Carlomagno, C., Matano, E., Bianco, R., Cimminiello, C., Prudente, A., Pagliarulo, C. ... De Placido, S. (2010). Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors . Experimental and Therapeutic Medicine, 1, 611-617. https://doi.org/10.3892/etm_00000096
MLA
Carlomagno, C., Matano, E., Bianco, R., Cimminiello, C., Prudente, A., Pagliarulo, C., Crispo, A., Cannella, L., De Stefano, A., D'Armiento, F. P., De Placido, S."Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors ". Experimental and Therapeutic Medicine 1.4 (2010): 611-617.
Chicago
Carlomagno, C., Matano, E., Bianco, R., Cimminiello, C., Prudente, A., Pagliarulo, C., Crispo, A., Cannella, L., De Stefano, A., D'Armiento, F. P., De Placido, S."Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors ". Experimental and Therapeutic Medicine 1, no. 4 (2010): 611-617. https://doi.org/10.3892/etm_00000096